

North East London (NEL) Interim Positional Statement for the use of Dexcom ONE real time Continuous Glucose Monitor

The National Institute for Health and Care Excellence (NICE) have updated the recommendations in relation to glucose monitoring for both Type 1 and Type 2 diabetes.

- [NICE NG17 Type 1 diabetes in adults](#) recommends wider eligibility for either intermittently scanned continuous glucose monitoring (isCGM) known as “Flash” such as the FreeStyle Libre system, or real time continuous glucose monitoring (rtCGM).
- [NICE NG18 Diabetes type 1 and type 2 in children and young people](#) recommends a wider eligibility for children with type 1 diabetes to have access to rtCGM or Flash
- [NICE NG28 Type 2 diabetes in adults](#) recommends eligibility for either intermittently scanned continuous glucose monitoring (isCGM) or the consideration of real-time continuous glucose monitoring (rtCGM) as an alternative to isCGM for adults with insulin-treated type 2 diabetes if it is available for the same or lower cost.

Consequently, Dexcom One rtCGM (transmitter and sensor) was added to the Drug Tariff in April 2023 which means it could be prescribed on FP10 prescription forms for specific criteria in primary care.

NEL Integrated Care System is currently in the process of developing the clinical pathway and approach for wider access to CGMs including Dexcom One and for inclusion into local medicines formulary.

Prescribing recommendations

- **Primary Care Clinicians are advised not to initiate Dexcom One (sensors and transmitters) until a NEL guidance is developed and approved by the NEL Formulary and Pathway Group.**
- **Where Dexcom One is already being recommended/prescribed for people living with type 1 diabetes, and prescribing has been transferred to primary care, prescribing can continue in primary care. Secondary care should provide primary care clinicians with the appropriate clinical and prescribing information.**
- **All new prescriptions of Dexcom One should be put on hold until the NEL pathway is in place. It should definitely not be initiated for type 2 Diabetes. A pan-London pathway for Type 2 diabetes is currently is being developed in collaboration with the London Clinical Networks and London Integrated Care Systems. Once this is available, a local pathway would be developed and implemented.**

Although NICE guidelines are not mandatory (unlike NICE Technology Appraisals), North East London health system acknowledges the importance of these guidelines and therefore is taking into consideration their application, and affordability when developing local guidance that is equitable and cost-effective. NEL is working collaboratively with other London health systems, partners and stakeholders to develop and implementation an approach that will enable equitable access to CGMs for people living with diabetes. Once completed, the local guidance and further information will be released in due course.

For any enquiries, contact the NEL Pharmacy and Medicines Optimisation Team.

- Tower Hamlets, Newham & Waltham Forest (TNW): nelondonicb.TNWmedicinesoptimisation@nhs.net
- Barking & Dagenham, Havering and Redbridge (BHR): bhrmedicines.management@nhs.net
- City & Hackney (C&H): <mailto:nelondonicb.cahmedicines@nhs.net>

Document control	
Version	1
Produced by	NEL Diabetes Clinical Network and Pharmacy and Medicines Optimisation Team
Approved by	North East London Formulary & Pathways Group (FPG)
Date approved	06/06/2023
Ratified by	North East London Integrated Medicines Optimisation & Prescribing Group (IMOC)
Date ratified	27/06/2023
Review date	27/06/2024